uniQure N.V Asset Resilience Ratio
uniQure N.V asset resilience ratio. uniQure N.V (UQ1) has an Asset Resilience Ratio of 57.35% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See UQ1 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of uniQure N.V (2021–2025)
Asset resilience ratio of uniQure N.V from 2021 to 2025. This chart shows how uniQure N.V's Asset Resilience Ratio has changed over time. Read total liabilities of uniQure N.V for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down uniQure N.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see UQ1 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €446.56 Million | 57.35% |
| Total Liquid Assets | €446.56 Million | 57.35% |
Asset Resilience Insights
- Very High Liquidity: uniQure N.V maintains exceptional liquid asset reserves at 57.35% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
uniQure N.V Industry Peers by Asset Resilience Ratio
Compare uniQure N.V's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
uniQure N.V Asset Resilience Ratio by Year (2021–2025)
uniQure N.V asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for uniQure N.V.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 65.74% | €542.30 Million ≈ $634.01 Million |
€824.91 Million ≈ $964.40 Million |
+28.26pp |
| 2024-12-31 | 37.48% | €208.59 Million ≈ $243.86 Million |
€556.54 Million ≈ $650.65 Million |
-7.79pp |
| 2023-12-31 | 45.27% | €376.53 Million ≈ $440.21 Million |
€831.69 Million ≈ $972.33 Million |
+27.57pp |
| 2022-12-31 | 17.71% | €124.83 Million ≈ $145.94 Million |
€704.96 Million ≈ $824.18 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€809.18 Million ≈ $946.02 Million |
-- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more